NCT07211308

Brief Summary

Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of Persistent Spinal Pain Syndrome Type II (PSPS-T2). Identification of clinical effective parameters concerning frequency, pulse duration, amplitude and battery consumption/recharge frequency and safety evaluation.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
33mo left

Started Oct 2025

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
Oct 2025Jan 2029

First Submitted

Initial submission to the registry

November 7, 2024

Completed
11 months until next milestone

Study Start

First participant enrolled

October 1, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 7, 2025

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2028

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2029

Last Updated

October 7, 2025

Status Verified

September 1, 2025

Enrollment Period

2.3 years

First QC Date

November 7, 2024

Last Update Submit

September 29, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Overall pain intensity

    The primary effectiveness outcome measure is pain intensity measured with the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 100 (maximal pain) in electronic format. Two scales will be presented for low back/neck pain and for leg/arm pain. Ecological momentary Assessment (EMA) will be used to collect pain intensity scores for VAS, whereby pain intensity is measured for multiple times per day for 1 week to reveal patterns of transient or fluctuating symptoms in the environment and context of the patients' lives, without a recall bias.

    The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Secondary Outcomes (20)

  • Pain intensity for the lower back and leg pain or neck and arm pain component

    The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

  • Medication use

    The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

  • Negative affect

    The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

  • Functional disability

    The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

  • Health related quality of life

    The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

  • +15 more secondary outcomes

Interventions

Differential target multiplexed stimulation

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.

You may qualify if:

  • having chronic pain as a result of PSPS-T2 that exists for at least 6 months with at least moderate pain intensity (4 or higher measured on numeric rating scale (NRS) or 31mm or higher measured on visual analogue scale (VAS) for the dominant pain location.
  • being offered treatment with DTM SCS
  • being at least 18 years old

You may not qualify if:

  • Expected inability of patients to properly operate the SCS system
  • History of coagulation disorders, lupus erythematosus, diabetic neuropathy
  • Active malignancy
  • Addiction to drugs and/or alcohol (more than 5 units /day)
  • Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact perception of pain, compliance to intervention and/or ability to complete questionnaires, as determined by the investigator
  • Immune deficiency (e.g. HIV positive, immunosuppressiva)
  • Life expectancy \< 1 year
  • Local infection or other skin disorder at site of incision
  • Pregnancy
  • Other implanted active medical device

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

UZ Brussel

Brussels, Belgium

Location

Vitaz

Sint-Niklaas, Belgium

Location

MeSH Terms

Conditions

Failed Back Surgery Syndrome

Interventions

Spinal Cord Stimulation

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsBack PainPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsPhysical Therapy ModalitiesRehabilitation

Central Study Contacts

Maarten TA Moens, MD, PhD

CONTACT

Lisa Goudman, PT, MSc, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 7, 2024

First Posted

October 7, 2025

Study Start

October 1, 2025

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2029

Last Updated

October 7, 2025

Record last verified: 2025-09

Locations